Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
With its innovative modular technology platform and fully integrated organizational approach, DiNAQOR AG is progressing the development and delivery of therapies for devastating genetic diseases of the heart, kidney and other organs.
The promise of accessing tissues beyond the liver is driving deals between pioneers in the field of nucleic-acid-based drugs and companies developing delivery platforms.
Bio-Techne combines expertise in exosome technologies with experience in the non-invasive liquid biopsy market to create solutions for companion diagnostic development and translational biomarker assay development services for biopharmaceuticals.
Pennsylvania-based SEED Therapeutics has leveraged the unmatched expertise of its founding team to develop a target-first molecular glue discovery platform.
By combining molecular science and artificial intelligence with years of experience and a world-leading database, Caris Life Sciences aims to revolutionize cancer care and deliver on the promise of precision oncology medicine in partnership with biopharma and industry innovators.
Harnessing its selective organ targeting lipid nanoparticle platform technology, ReCode Therapeutics is facilitating precision delivery of genetic cargos directly to their intended organs and cells.
SMC Laboratories, Inc. (SMC) is a Japan-based contract research organization with a focus on preclinical development in inflammation, fibrosis and oncology.
Pharma companies and regulatory agencies recognize how real-world data can enhance drug development from target identification to clinical trials. BC Platforms provides broad and secure access to this valuable resource in addition to critical tools, interoperable infrastructure, and expertise.
Vaccination saves two to three million lives annually. GSK will continue delivering proven vaccines, expand their availability to populations in need, and create new vaccines to protect against endemic and emerging diseases. To those who possess novel technologies that can innovate vaccine creation, GSK ventures to be your partner of choice.
SAB Biotherapeutics’ DiversitAb novel drug development platform creates targeted fully human multi-epitope binding immunoglobulins (polyclonal antibodies) without the need for human donors. Its proprietary immunotherapies show promise for treating and preventing infectious diseases and autoimmune and oncological disorders.
The evolution of antifungal resistance is undermining the armamentarium of antifungal therapeutics and threatens novel agents coming through the pipeline. F2G, an antifungal-focused biopharma company, is addressing the need for medicines to treat fungal infections, which is hard but not insurmountable.
Clinical stage company Evaxion Biotech is using artificial intelligence (AI) to simulate the immune system and create predictive models to identify novel targets for vaccines against bacterial and viral diseases and immunotherapies for cancer.
Attivare Therapeutics is developing vaccines that offer an amplified humoral and cellular immune response to target infectious diseases with a single-shot option.
Leonard Lee, head of growth and customer success for Accelerated Discovery at IBM, discusses the ways AI is transforming drug discovery and assisting scientists today.
The potential of companies developing artificial intelligence (AI)-based tools for drug discovery and development has driven investment and deals with major biopharma companies, but challenges for AI biotechs and biopharma companies are emerging as the field moves beyond the hype towards impact.
Taking an innovative approach to applying artificial intelligence (AI) to medical imaging, Quibim is designing predictive panels to enable healthcare providers to improve patient outcomes.
TeselaGen’s artificial intelligence-enabled operating system for designing, building, and optimizing bio-based products is driving innovation across the biotechnology sector.
